VenoVision non-invasively provides the advanced cardiac monitoring needed to better personalize therapy for millions of heart failure and at-risk patients in the hospital and home in an underserved $33B market.
VenoVision uses thermal imaging and ML to deliver central venous pressure and waveform hemodynamic insights - previously limited to implants and catheterizations - enabling deterioration to be spotted sooner and therapy to be guided more closely. With VenoVision's easy-to-use, "point-&-press" device, medical teams can improve patient stability and drive down the billions of dollars spent on avoidable days in the ICU and hospital.
We’re proud to be a Delaware C-Corp with Israeli origins!
VenoVision was conceptualized in the Hebrew University of Jerusalem’s BioDesign Program and carried out its proof-of-concept clinical trial at Shaare Zedek Medical Center. It won "most innovative" award at M2D2 Impact 2023, it is an alum of MassChallenge (Israel 2021), and it is a Health Wildcatters accelerator (Dallas, Texas) 2022-23 portfolio company.
Company Details
- Founded
- 2022
- Address
- Delaware, Us
- Industry
- Hospitals And Health Care
- NAICS
-
Health Care and Social AssistanceSocial Assistance
- Website
- https://venovision.com
- Keywords
- Geneva.
- HQ
- Delaware
Venovision Questions
Venovision's website is https://venovision.com
Venovision's LinkedIn profile is https://www.linkedin.com/company/venovision
Venovision's industry is
Hospitals and Health Care
Venovision's top competitors are
Fergus Medical,
Areno | Fitness & Wellness,
Yada Properties,
Cormedic S.a. | Sveltia,
Pistachio,
Genspire,
Polka Pop,
Moodforest,
Reachifyme,
Kenes Group.
Venovision's categories are Hospitals and Health Care
Venovision's founding year is 2022
